Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, +166

The Lancet

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, +26

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMedicineLong-term Clinical OutcomesImmunology +6

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç, +157

The Lancet Oncology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy +4

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold, +187

The Lancet

Regenerative MedicineCell TherapyTransplantationMarrow TransplantationPlacebo-controlled Phase 3 +5

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Stephen Peeke, Nishi Shah, Jennat Mustafa, +20

Journal of Hematology & Oncology

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

Murali Janakiram, Jordan M. Chinai, Susan Fineberg, +11

Clinical Cancer Research

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram, Jordan M. Chinai, Aimin Zhao, +2

OncoImmunology

Novel Immunosuppressive MechanismAdaptive Immune SystemImmunologyImmunoeditingImmunologic Mechanism +16

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Daniel A. Rauch, Kevin C. Conlon, Murali Janakiram, +15

Blood

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

Haiying Cheng, Murali Janakiram, Alain Borczuk, +7

Clinical Cancer Research

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, +26

Blood Cancer Journal